Fără conexiune la internet — se afișează versiunea salvată a paginii.

Mesoblast Ltd

USUSD
← Către filtru
US:MEOBFAU:MSB

Mesoblast Ltd (AU:MSB) — Biotechnology: Biological Products (No Diagnostic Substances). Numărul de burse pe care se tranzacționează acțiunile companiei: 2. Pe această pagină — preț și grafic, dividende, principalii deținători și istoricul numărului de acțiuni.

Despre companie

Site web
mesoblast.com
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sediu central
MELBOURNE, VICTORIA, Australia
Director general
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Angajați
108
Acțiuni în circulație
1.3 mld. la 2026-06-30
Free float
861.1 mil.
Capitalizare de piață
1.48 mld. USD
Insideri
36.28%
Investitori instituționali
17.44%
Industrie (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
AU000000MSB8
Descriere

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Burse și simboluri

BursăSimbolMonedăPrețTip
US USA StocksMEOBF OTCUSD1.39 +21.93%acțiuni ordinare
AU Australian Securities ExchangeMSB principalăAUD—acțiuni ordinare

Preț pe 3 luni

zi de creștere zi de scădere data ex-dividend data plățiiTreceți cu mouse-ul / atingeți o zi — prețurile de deschidere, închidere, maxim și minim

Dividende

Nu s-au găsit plăți de dividende (verificat 07.10.2026). Probabil că societatea nu plătește dividende.

Știri din această săptămână

Încă nu există știri de pe site-ul companiei.

publicitate

Cei mai mari acționari

DeținătorParticipațieAcțiuniData raportului
Itescu (Silviu) (Chief E…≈6.23%80.84 mil.2026-07-17
VANGUARD STAR FUNDS-Vang…1.05%13.66 mil.2026-04-30
VANGUARD TAX-MANAGED FUN…0.62%8.01 mil.2026-06-30
iShares Trust-iShares Co…0.53%6.88 mil.2026-07-31
Rose (Eric) (Director (N…≈0.52%6.75 mil.2026-01-09
DFA INVESTMENT TRUST CO-…0.36%4.68 mil.2026-04-30
VANGUARD Intl Eqy. INDEX…0.27%3.51 mil.2026-04-30
iShares Trust-iShares MS…0.24%3.07 mil.2026-07-31
SCHWAB STRATEGIC TRUST-S…0.15%1.99 mil.2026-05-31
Dimensional ETF Trust-Di…0.11%1.38 mil.2026-04-30
iShares Trust-iShares Co…0.09%1.23 mil.2026-07-31
SPDR INDEX SHARES Fd.S-S…0.09%1.19 mil.2026-08-31
Bell (Jane Catherine) (D…≈0.05%622 4922025-02-28
Burns (William) (Indepen…≈0.02%226 2502025-10-21
Legato Capital Managemen…0.01%47 3802022-06-30
Cobley (Lyn Elizabeth) (…≈0%63 0002026-01-09